Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Eagle Pharmaceuticals, Inc. (EGRX) had Normalized Income after Taxes of $5.16M for the most recently reported fiscal quarter, ending 2023-06-30.
| Income Statement Financials | |
$64.65M |
|
$5.16M |
|
$16.86M |
|
$47.79M |
|
$54.34M |
|
$10.30M |
|
$-1.01M |
|
$9.30M |
|
$9.30M |
|
$5.16M |
|
$5.16M |
|
$5.16M |
|
|
Normalized Income after Taxes |
$5.16M |
$10.30M |
|
$16.73M |
|
13.09M |
|
13.15M |
|
$0.39 |
|
$0.39 |
|
| Balance Sheet Financials | |
$187.25M |
|
$1.01M |
|
$217.57M |
|
$404.82M |
|
$86.63M |
|
$61.90M |
|
$66.15M |
|
$152.78M |
|
$252.04M |
|
$99.60M |
|
$252.04M |
|
13.10M |
|
| Cash Flow Statement Financials | |
$-33.64M |
|
$-12.56M |
|
$6.24M |
|
$55.32M |
|
$15.35M |
|
$-39.97M |
|
$8.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.16 |
|
-- |
|
-- |
|
0.20 |
|
0.28 |
|
73.92% |
|
15.94% |
|
15.94% |
|
-- |
|
14.38% |
|
7.99% |
|
$-33.70M |
|
-- |
|
-- |
|
-- |
|
0.16 |
|
0.40 |
|
0.56 |
|
160.30 |
|
2.05% |
|
5.18% |
|
1.28% |
|
1.64% |
|
$19.25 |
|
$-2.56 |
|
$-2.56 |
|